Study of Irinotecan Liposomes for Rectal Cancer Before Surgery
Treatments studied
Part of Cancer clinical trials.
This trial tests adding irinotecan liposomes to standard treatment for locally advanced rectal cancer before surgery. The goal is to see if this combination works better at shrinking the tumor and preventing it from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have rectal adenocarcinoma confirmed by biopsy.
- Your tumor is stage T3-4 or has spread to nearby lymph nodes (N+).
- The lower edge of the tumor is within 10 cm of the anal opening.
- You are in good physical condition (ECOG score of 0 or 1).
- Your UGT1A1 gene test results show a low-risk type (wild-type or single-site mutation).
- You have not had any previous treatment for rectal cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether adjusting irinotecan treatment based on a person’s UGT1A1 gene test can improve outcomes for locally advanced rectal cancer. It focuses on people who are about to start (or continue) chemoradiation and do not have cancer spread to distant organs.
This trial tests a new form of chemotherapy (liposomal irinotecan) combined with two standard drugs (5-FU and leucovorin) and a targeted therapy (bevacizumab) for people with advanced colorectal cancer that cannot be removed by surgery. The goal is to see if this combination shrinks tumors and helps people live longer.
This trial tests a new form of the chemotherapy drug irinotecan (called irinotecan liposome) combined with two other chemo drugs and a targeted therapy (bevacizumab) for people with advanced colorectal cancer that has already been treated with oxaliplatin. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial tests a new combination of radiation, chemotherapy (NALIRIF), and an immunotherapy drug (PD-1 antibody) for rectal cancer that has come back in the pelvis. The goal is to see if this approach can help control the cancer better.
This study tests a new form of chemotherapy called liposomal irinotecan (Nal-IRI) for people with advanced colorectal cancer or other solid tumors. The goal is to see how well it works and how safe it is in real-world settings.
This trial tests a new chemotherapy drug called liposomal irinotecan as a second treatment for metastatic colorectal cancer (cancer that has spread beyond the colon or rectum). You would be eligible if your cancer progressed after your first chemotherapy treatment and you're in good enough health to receive more treatment.
Hear when a new Locally Advanced Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.